# Self-Healing Hydrogels: Development, Biomedical Applications, and Challenges

**Authors:** Md. Mahamudul Hasan Rumon, Anwarul Azim Akib, Fahmida Sultana, Md. Moniruzzaman, Mahruba Sultana Niloy, Md Salman Shakil, Chanchal Kumar Roy

PMC · DOI: 10.3390/polym14214539 · 2022-10-26

## TL;DR

Self-healing hydrogels are promising biomedical materials with applications in tissue engineering and drug delivery, but challenges remain in balancing their mechanical properties and long-term effects.

## Contribution

This review provides an overview of the mechanisms, recent advancements, and challenges of self-healing hydrogels in biomedical applications.

## Key findings

- Self-healing hydrogels respond to external stimuli like pH and temperature, making them adaptable for biomedical use.
- Key challenges include balancing healing performance with mechanical toughness and understanding long-term in vivo effects.
- Recent advancements in SHH have shown promise in tissue engineering, wound healing, and drug delivery.

## Abstract

Polymeric hydrogels have drawn considerable attention as a biomedical material for their unique mechanical and chemical properties, which are very similar to natural tissues. Among the conventional hydrogel materials, self-healing hydrogels (SHH) are showing their promise in biomedical applications in tissue engineering, wound healing, and drug delivery. Additionally, their responses can be controlled via external stimuli (e.g., pH, temperature, pressure, or radiation). Identifying a suitable combination of viscous and elastic materials, lipophilicity and biocompatibility are crucial challenges in the development of SHH. Furthermore, the trade-off relation between the healing performance and the mechanical toughness also limits their real-time applications. Additionally, short-term and long-term effects of many SHH in the in vivo model are yet to be reported. This review will discuss the mechanism of various SHH, their recent advancements, and their challenges in tissue engineering, wound healing, and drug delivery.

## Full-text entities

- **Genes:** DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Mtpn (myotrophin) [NCBI Gene 14489] {aka 5033418D15Rik, Gcdp, V1}, TGFB2 (transforming growth factor beta 2) [NCBI Gene 7042] {aka CAEND2, G-TSF, LDS4, TGF-beta2}, Dcn (decorin) [NCBI Gene 29139], ngfra (nerve growth factor receptor a (TNFR superfamily, member 16)) [NCBI Gene 100535003] {aka ngfr, receptor, si:busm1-107d16.1, si:dkey-146h23.1, si:dz107d16.1, si:dz94e17.1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}
- **Diseases:** diabetic (MESH:D003920), breast cancer (MESH:D001943), burn (MESH:D002056), cancer (MESH:D009369), necrotic (MESH:D009336), CNS-impaired (MESH:D002493), retinal scars (MESH:D012173), inflammation (MESH:D007249), ischemic (MESH:D002545), Myocardial infarction (MESH:D009203), SHH (MESH:C536150), cytotoxic (MESH:D064420), hepatocellular carcinoma (MESH:D006528), infarcted myocardium (MESH:D007238), neurodegenerative diseases (MESH:D019636), infection (MESH:D007239), hypoxia (MESH:D000860), corneal damage (MESH:D065306)
- **Chemicals:** Polymer (MESH:D011108), benzaldehyde (MESH:C032175), glucose (MESH:D005947), diol (MESH:D011276), N-AD (MESH:D009243), Fe (MESH:D007501), EDTA (MESH:D004492), phenylboronic acid (MESH:C010686), AM (MESH:D000576), SDS (MESH:D012967), NaBr (MESH:C027938), UPy (MESH:C000710651), Fc (MESH:C095424), C18) (MESH:C109760), adipic acid (MESH:C029900), Hydroxyl radical (MESH:D017665), 1,2-dithiolane (MESH:C448825), beta-CD (MESH:C031215), H2O2 (MESH:D006861), polyelectrolytes (MESH:D000071228), PEGDA (MESH:C437167), N,N'-dimethylacrylamide (MESH:C099046), cyclodextrin (MESH:D003505), Chitosan (MESH:D048271), Acrylic acid (MESH:C036658), amine (MESH:D000588), polysaccharide (MESH:D011134), cucurbituril (MESH:C513894), DMA (MESH:C405765), Borax (MESH:C018851), N,O-carboxymethyl chitosan (MESH:C077199), antimicrobial peptide (MESH:D000089882), OA (MESH:D019319), C (MESH:D002244), gellan gum (MESH:C048288), azobenzene (MESH:C009850), HA (MESH:D006820), thiol (MESH:D013438), graphene (MESH:D006108), poly(N-isopropyl-acrylamide) (MESH:C052970), Ag+ (MESH:D012834), DTT (MESH:D004229), guanosine (MESH:D006151), aldehyde (MESH:D000447), cytosine (MESH:D003596), Schiff base (MESH:D012545), .OH (MESH:C031356), PAM hydrogel (MESH:C016680), metal (MESH:D008670), poly(acrylic acid) (MESH:C006903), glycol chitosan (MESH:C118638), cellulose (MESH:D002482), Polyvinyl alcohol (MESH:D011142), DOX (MESH:D004317), poly (ethylene glycol) (MESH:D011092), N-carboxyethyl chitosan (MESH:C000711988), Acrylamide (MESH:D020106), oxygen (MESH:D010100), Ferrocene (MESH:C004998), salt (MESH:D012492)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Escherichia coli (E. coli, species) [taxon 562], Danio rerio (leopard danio, species) [taxon 7955], Actinopterygii (fishes, superclass) [taxon 7898], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), L-929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HEK-293 human — Homo sapiens (Human), Transformed cell line (CVCL_0045), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9654449/full.md

---
Source: https://tomesphere.com/paper/PMC9654449